https://onkoresearch.com/index.php/onkoresearch/gateway/plugin/WebFeedGatewayPlugin/atomONKORESEARCH2023-12-18T08:33:58-05:00Deisy Shudey Tarazona Lopezonkoresearch@gmail.comOpen Journal Systemshttps://onkoresearch.com/index.php/onkoresearch/article/view/29Updated overview of first-line treatment for diffuse large B-cell non-Hodgkin lymphoma2023-12-18T10:45:27-05:00Jianmartin GalecioCindy AlcarrazDenisse Castro-Uriol
<p>The therapeutic approach to Diffuse Large B-Cell Lymphoma (DLBCL) is based on the curative intent of the treatment regardless of its clinical stage and the presence of poor prognostic factors. Chemoimmunotherapy remains the standard treatment, with or without radiation therapy. Monoclonal antibodies have shown significant improvement in survival and are currently being incorporated into first-line treatment at the onset of the disease. Novel therapies have shown encouraging results for the first line, however data still immature and not yet better than the standard of care. Remarkably, first-line treatment involves certain considerations that we should take into account in clinical situations such as older age, pregnancy, HIV infection, resected and extranodal disease.</p>
2023-12-17T00:00:00-05:00Copyright (c) 2023 Jianmartin Galeciohttps://onkoresearch.com/index.php/onkoresearch/article/view/27A case report of blastic plasmocytoid dendritic cell neoplasm in a pediatric patient: an unusual age of presentation2023-11-29T08:29:05-05:00Melissa Morales-Coloma
<p>Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN) is a rare type of cancer with aggressive behavior, most commonly found in adults. However, it is very uncommon in children, and documented evidence is limited. Herein, we present the case of a 6-year-old patient diagnosed and treated at the National Institute of Health for Children in Lima.</p>
2023-11-28T00:00:00-05:00Copyright (c) 2023 Melissa Morales-Colomahttps://onkoresearch.com/index.php/onkoresearch/article/view/25A case report of pleuropulmonary blastoma: a challenging diagnostic and therapeutic path in pediatrics2023-11-29T08:28:26-05:00Gloria ParedesOmar ReyesSomocurcio JoséAlex Rivera del Carpio
<p>3-year-old female with a history of bullectomy at the age of 1-year-old, presented a course of progressive respiratory difficulty, dry cough and fever. Extension studies showed a solid tumor that covered almost the entire right hemithorax, displacing the mediastinum. An upper right lobectomy and lumpectomy were performed but a residual mass remained after surgery. Pleuropulmonary blastoma (PPB) type II-III with DICER 1 germinal mutation was diagnosed. She received the IVADo regimen, reducing the tumor size; however, the remaining residual tumor was inoperable. Consequently, she proceeded with a maintenance phase using the Vinorelbine/Cyclophosphamide regimen, being both regimens part of the non-standardized RMS-2005 protocol. A biopsy of the residual mass reported non evidence of cancer. After a 2-year follow-up, she remains cancer-free. This is a very rare disease lacking a standardized treatment protocol until now. It is associated with a genetic basis in 40% of it cases, linked to DICER1 mutation, and typically manifests within the first five years of life. The multidisciplinary management is key in this disease that can improve improves survival.</p>
2023-09-15T00:00:00-05:00Copyright (c) 2023 Gloria Paredes, Omar Reyes, José Somocurcio, Alex Rivera del Carpiohttps://onkoresearch.com/index.php/onkoresearch/article/view/23Epidemiology as a resource for informing cancer control guidelines and policies in Peru2023-06-08T20:45:05-05:00Bryan Valcarcel2023-06-08T00:00:00-05:00Copyright (c) 2023 Bryan Valcarcelhttps://onkoresearch.com/index.php/onkoresearch/article/view/19Cervical embryonal rhabdomyosarcoma: a case series from a single-institution2022-11-04T08:23:19-05:00Miguel MatuteLiliana VasquezDarshi ShahRosario Rivera
<p>Rhabdomyosarcoma is an aggressive malignant neoplasm that originates in the mesenchyme. It is the most frequent type of sarcoma in infants and children. Its localization in the uterus is extremely rare, and its incidence increase from 20 years-old onwards. Prognosis typically depends on the histological type, age, and the absence of metastasis. We present 5 cases of young females with a history of bleeding, a cervical tumor, whose biopsy was positive for embryonal rhabdomyosarcoma, botryoid variant. All patients received chemotherapy and surgery. Since rhabdomyosarcoma has a high rate of incidence in young women and its diagnosis in the cervix is less aggressive, conservative management of these cases is recommended fertility preservation. Post-surgical management should always consist of chemotherapy, as advances in this type of therapy have been shown to improve general survival rates. Hence, it is essential to report on rare tumors, as it helps in acquiring experience and appropriate knowledge for their clinical management and raises the need for further studies on this disease.</p>
2022-10-30T00:00:00-05:00Copyright (c) 2022 Miguel Matute, Liliana Vasquez, Darshi Shah, Rosario Riverahttps://onkoresearch.com/index.php/onkoresearch/article/view/18Genetic counseling, testing and management of prostate adenocarcinoma patients: recommendations from a consensus of experts from the National Institute of Neoplastic Diseases of Peru2022-10-31T16:30:37-05:00Silvia P. NeciosupHenry L. GómezAnalí P. MoraRossana RuizCarlos A. CastañedaZaida D. MoranteNatalia I. ValdiviesoJosé R. Pieschacón
<p>The objective was to provide tools for genetic profiling and treatment of patients with prostate adenocarcinoma. The Consensus was made up of oncologists and geneticists from the National Institute of Neoplastic Diseases of Peru and followed the guidelines of the “Consensus Conference on Standard Operating Procedures of the European Society of Medical Oncology”. The GRADE methodology was applied to assess the evidence and make recommendations. The clinical practice guidelines were graded following the "AGREE II". All patients with prostate adenocarcinoma and risk factors should be ordered genetic testing and counseling; Testing should include <em>BRCA1/2, ATM, CHECK2 PALB2, MLH1, MSH2/6, </em>and <em>PMS2</em>. Additional genes may be requested based on the clinical condition. In patients with metastatic castration-resistant or regional prostate cancer, somatic testing may be considered. The result of the test can guide the treatment. In conclusion, there are many unmet needs in the approach and management of prostate cancer. Cancer genetic risk assessment and genetic counseling involves the identification and counseling of individuals at risk for hereditary cancer. Genetic counseling and testing are expected to be included in daily clinical practice.</p>
2022-10-30T00:00:00-05:00Copyright (c) 2022 Silvia P. Neciosup, Henry L. Gómez, Analí P. Mora, Rossana Ruiz, Carlos A. Castañeda, Zaida D. Morante, Natalia I. Valdivieso, José R. Pieschacónhttps://onkoresearch.com/index.php/onkoresearch/article/view/17Genetic counseling, testing and management of epithelial ovarian carcinoma patients: recommendations from a consensus of experts from the National Institute of Neoplastic Diseases of Peru2022-10-31T16:30:37-05:00Silvia P. NeciosupHenry L. GómezAnalí P. MoraRossana RuizCarlos A. CastañedaZaida D. MoranteNatalia I. ValdiviesoJosé R. Pieschacón
<p>The objective was to provide tools for the profiling and management of patients with epithelial ovarian cancer through genetic testing. The Consensus was made up of experts in oncology and genetics from the National Institute of Neoplastic Diseases of Peru and followed the guidelines of the Consensus Conference on Standard Operating Procedures of the European Society of Medical Oncology. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology was used to assess the evidence and make recommendations. The clinical practice guidelines were graded following the Appraisal of Guidelines for Research and Evaluation instrument II (AGREE II). Genetic counseling and testing is recommended for all patients with epithelial ovarian cancer. Regardless of the findings in the tumor, germinal testing should be performed. Testing is suggested to include BRCA1, BRCA2, ATM, BRIP1, MLH1, MSH2, MSH6, PALB2, RAD51C, RAD51D, TP53, PTEN, PMS2, EPCAM and NBN. Test findings can guide pharmacological treatment. In conclusion, patients with epithelial ovarian cancer and their relatives at risk should be identified and provided with genetic counseling. The recommendations given in this consensus will be useful if they are known and implemented. Genetic counseling and testing are expected to be included in daily clinical practice.</p>
2022-10-30T00:00:00-05:00Copyright (c) 2022 Silvia P. Neciosup, Henry L. Gómez, Analí P. Mora, Rossana Ruiz, Carlos A. Castañeda, Zaida D. Morante, Natalia I. Valdivieso, José R. Pieschacónhttps://onkoresearch.com/index.php/onkoresearch/article/view/16Survival in adolescents and young adults with B-cell non-Hodgkin's lymphoma in a referral hospital in Peru2022-11-04T08:20:33-05:00Ligia RiosDenisse CastroLiliana VásquezJenny Geronimo
<p><strong>Objective: </strong>for adolescents and young adults with B-cell non-Hodgkin lymphoma in Peru. <strong>Materials and methods: </strong>This retrospective study included patients aged 10-39 years with B-cell non-Hodgkin lymphoma (2010-2016). Characteristics were analyzed using Fisher’s exact test, and survival differences were compared. <strong>Results: </strong>Thirty-one adolescents and young adult patients (6 with pediatric regimens, and 25 with adult regimens) were included. The 3-year overall survival rate was 100% for the pediatric group and 64% for the adult group (p=0.13). The only patient in the pediatric regimen who relapsed, achieved a second complete remission with Rituximab plus ifosfamide, carboplatin, etoposide and autologous stem cell transplantation, while all patients of the adult regimen group died of progressive disease. <strong>Conclusions: </strong>our findings suggest that adolescents and young adults with the diagnosis of B-cell Non-Hodgkin’s lymphoma have better survival rates in comparison to those who are treated with adult regimens. Multicenter studies with a larger number of patients are required to confirm these results.</p>
2022-10-30T00:00:00-05:00Copyright (c) 2022 Ligia Rios, Denisse Castro, Liliana Vásquez, Jenny Geronimohttps://onkoresearch.com/index.php/onkoresearch/article/view/15Out-of-pocket expenditure in childhood cancer during the COVID-19 pandemic in Peru2022-10-31T16:30:39-05:00Essy MaradiegueIvan MazaSharon ChavezLourdes ArandaClaudia PascualHenry GarcíaRodolfo ParedesCarolina RiojasMiguel GonzalesAnnaly BenaventeIsabel HurtadoChristopher MachadoEric MattosVíctor PalaciosMariela TelloLiliana Vasquez
<p>Background: The COVID-19 pandemic has led to unprecedented economic and health vulnerability and inequities globally. Objective: This study examines the out-of-pocket expenses assumed by parents of children and adolescents with cancer in Peru during the COVID-19 pandemic and compares them to those corresponding to the pre-COVID era. Materials and methods: We conducted a cross-sectional survey of parents and caregivers of pediatric cancer patients who were cared for in public and private institutions between October and November 2020. All of them gave their consent before completing the survey. Respondent parents of children diagnosed before March 2020 were considered the pre-COVID-19 pandemic group, whereas if the definitive diagnosis was made after this date, it was classified as part of the COVID-19 group. Results: A total of 222 parents and caregivers of children with cancer responded to the survey. Almost half of the respondents lived in Lima. The average monthly family income was USD 388.4 and USD 314.7 before and during the COVID-19 pandemic. The average expenditure was USD 487.0 (SD, 453.5) and USD 415 (SD, 414.5) before and during the COVID-19 pandemic, before the cancer diagnosis. The average expenditure was USD 454.6 (SD, 406.7) and USD 387.5 (SD, 323.4) before and during the COVID-19 pandemic after a cancer diagnosis. In the COVID-19 group, the rate of catastrophic expenditure on these families was 86% before the definitive diagnosis and 75% after the cancer diagnosis. According to the type of cancer, families with a child diagnosed with a solid tumor had significantly higher out-of-pocket expenses than a leukemia than those with a child with leukemia prior to their diagnosis. Conclusion: Our study suggests that high out-of-pocket health expenses were frequent in families with a child with cancer in Peru during the COVID-19 pandemic. It is possible to infer that this situation was aggravated by the decrease in economic income of most families due to the disruption of formal and informal employment.</p>
2022-10-30T00:00:00-05:00Copyright (c) 2022 Essy Maradiegue, Ivan Maza, Sharon Chavez, Lourdes Aranda, Claudia Pascual, Henry García, Rodolfo Paredes, Carolina Riojas, Miguel Gonzales, Annaly Benavente, Isabel Hurtado, Christopher Machado, Eric Mattos, Víctor Palacios, Mariela Tello, Liliana Vasquezhttps://onkoresearch.com/index.php/onkoresearch/article/view/14Clinical characteristics and outcomes in cancer patients affected by COVID-19: a study from a Peruvian cancer center2022-11-04T08:17:14-05:00Rossana RuizZaida MoranteFernando NamucheAngela ArbizuClaudio FloresCarlos VallejosFrank YoungAlfredo AguilarLuis CastilloPaola MontenegroCarlos Seas
<p><strong>Objective: </strong>To describe the clinical features and outcomes of COVID-19 infection in cancer patients and evaluate the risk factors associated with severe disease. <strong>Materials and methods: </strong>An observational retrospective study was performed in Oncosalud-AUNA. We included patients with diagnosis of invasive cancer with a SARS-CoV-2 confirmed infection by RT-PCR assay. Univariate and multivariate binary logistic regression analysis were performed to evaluate the risk factors associated with severe desease. <strong>Results: </strong>A total of 36 patients were included. Median age was 61 years old; 36.1% males; 58.4% with ≥1 comorbidity. Breast cancer was the most frequent malignancy. 72% of patients were on anticáncer treatment. All patients were symptomatic. 16.7% were admitted to the ICU and 27.8% of patients died. The severity of disease was: mild, 27.8%; moderate, 33.3%; severe, 22.2%; and critical – ARDS, 16.7%. Patients with severe or critical disease were frequently ˃60 years old, male, in ECOG 2-3 and were receiving treatment with palliative intention. <strong>Conclusions: </strong>COVID-19 cancer patients were frequently overweight older adults with at least one comorbidity with active treatment and developed typical COVID-19 symptoms. Severe or critical COVID-19 occurred in more than one third of patients. Male patients and those ˃60 years old were at greater risk of developing severe or critical COVID-19.</p>
2022-10-30T00:00:00-05:00Copyright (c) 2022 Rossana Ruiz, Zaida Morante, Fernando Namuche, Angela Arbizu, Claudio Flores, Carlos Vallejos, Frank Young, Alfredo Aguilar, Luis Castillo, Paola Montenegro, Carlos Seashttps://onkoresearch.com/index.php/onkoresearch/article/view/13Current status of scientific publishing in Latam and Peru: challenges and opportunities2022-11-04T08:12:55-05:00Deisy S. TarazonaDenisse Castro2022-10-30T00:00:00-05:00Copyright (c) 2022 Deisy S.Tarazona, Denisse Castro